PPI network analysis identified TP53, SRC, AKT1, HSP90AA1, ESR1, EP300, JUN, EGFR, and HSP90AB1 as key targets in WQD’s therapeutic effects against GC. This evidence concerns the gene TP53 and gastric cancer.